Rituximab in steroid refractory autoimmune hemolytic anemia

Nineteen RCTs (820 children enrolled; 773 evaluated) were included. Most studies were small. Eleven studies were at low risk of bias for allocation concealment and only four studies were at low risk of performance bias . Fifteen, eight and 10 studies were at low risk of detection bias , attrition bias and reporting bias respectively. Cyclosporin when compared with placebo or no treatment significantly increased the number of children who achieved complete remission. However this was based on only eight children who achieved remission with cyclosporin compared with no children who achieved remission with placebo /no treatment in three small studies (49 children: RR , 95% CI to ). Calcineurin inhibitors significantly increased the number with complete or partial remission compared with IV cyclophosphamide (2 studies, 156 children: RR , 95% CI to ; I 2 = 20%). There was no significant differences in the number who achieved complete remission between tacrolimus versus cyclosporin (1 study , 41 children: RR , 95% CI to ), cyclosporin versus mycophenolate mofetil plus dexamethasone (1 study , 138 children: RR , 95% CI to ), oral cyclophosphamide with prednisone versus prednisone alone (2 studies, 91 children: RR , 95% CI to ), IV versus oral cyclophosphamide (1 study , 11 children: RR , 95% CI to ), IV cyclophosphamide versus oral cyclophosphamide plus IV dexamethasone (1 study , 49 children: RR , 95% CI to ), and azathioprine with prednisone versus prednisone alone (1 study , 31 children: RR , 95% CI to ). One study found no significant differences between three agents (cyclophosphamide, mycophenolate mofetil, leflunomide) used in combination with tacrolimus and prednisone. One study found no significant difference in the percentage reduction in proteinuria (31 children: -12; 95% CI -73 to 110) between rituximab with cyclosporin/prednisolone and cyclosporin/prednisolone alone. Two studies reported ACEi significantly reduced proteinuria.

Methotrexate is now considered the first-line DMARD agent for most patients with RA.  It has a relatively rapid onset of action at therapeutic doses (6-8 weeks), good efficacy, favorable toxicity profile, ease of administration, and relatively low cost. When looking at groups of patients on different DMARDS, the majority of patients continue to take Methotrexate after 5 years, far more than other therapies reflecting both its efficacy and tolerability.  Methotrexate is effective in reducing the signs and symptoms of RA, as well as slowing or halting radiographic damage. It was as effective as leflunomide and sulfasalazine in one study, and its effectiveness given early and in higher doses approached the efficacy of etanercept and adalimumab as single therapies in terms of signs and symptom improvement.  Methotrexate is also effective in many other forms of inflammatory arthritis including psoriatic arthritis and other spondyloarthopathies, and is used in many other autoimmune diseases.

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Rituximab in steroid refractory autoimmune hemolytic anemia

rituximab in steroid refractory autoimmune hemolytic anemia

Media:

rituximab in steroid refractory autoimmune hemolytic anemiarituximab in steroid refractory autoimmune hemolytic anemiarituximab in steroid refractory autoimmune hemolytic anemiarituximab in steroid refractory autoimmune hemolytic anemiarituximab in steroid refractory autoimmune hemolytic anemia

http://buy-steroids.org